Young Adults | Ancient Viruses | Cell Therapy, 09/11/2024

Having trouble viewing this email? View it as a Web page.

Cancer Information Highlights From the National Cancer Institute Updating you about cancer causes, prevention, screening, treatment, coping, and more   New from NCI Tackling the Emergence of Early-Onset Cancers in Young Adults   The rate of cancer among people between ages 18 and 49 has climbed by almost 80% since the 1990s. The roots of this change are poorly understood. The NCI Fiscal Year 2026 Annual Plan and Professional Judgment Budget Proposal describes how, with sustained funding, NCI is primed to develop treatments and prevention strategies specific to the unique needs of young adults with cancer. Read More DNA from Ancient Viruses Helps Many Cancers Grow   DNA fragments from retroviruses that are millions of years old appear to be active in a variety of cancers, a new study found. One virus-derived DNA fragment in particular, known as LTR10, turns on cancer-related genes in many types of cancer. Read More Engineered Cell Therapy Approved for Advanced Synovial Sarcoma   The Food and Drug Administration (FDA) approved afami-cel (Tecelra) to treat certain people with metastatic synovial sarcoma, a type of soft tissue sarcoma. Afami-cel is the first T-cell receptor therapy approved for cancer. Read More Cancer in Children and Adolescents This updated page provides statistics about cancer in children and teens in the United States. It also describes the common types, causes, and treatments for these cancers. Read More Growing the Cancer Research Pipeline by Expanding Opportunities   NCI Director Dr. Kimryn Rathmell and Division of Cancer Biology Director Dr. Dan Gallahan explain how the R15 grant program supports researchers at smaller institutions and encourages students to pursue careers in cancer research. Read More Durvalumab Approval Expands Treatment Options for Certain Lung Cancers FDA has approved durvalumab (Imfinzi) to treat adults with non-small cell lung cancer (NSCLC) that can be removed by surgery and does not have an abnormal EGFR or ALK gene. It is used with platinum-based chemotherapy before surgery and alone after surgery. Durvalumab was previously approved to treat NSCLC that cannot be removed by surgery and extensive-stage small cell lung cancer. Read More   Contact Us   Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. This page tells you how to reach us by phone, chat, or email.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892